Analysing the immune response and optimising the effectiveness of Mesothelin CAR T-cell therapy in cancer.

分析免疫反应并优化间皮素 CAR T 细胞治疗癌症的有效性。

• 批准号: nhmrc : GNT1169460
• 金额: $ 9.27万
• 依托单位国家: 澳大利亚
• 项目类别: Postgraduate Scholarships
• 财政年份: 2019
• 资助国家: 澳大利亚
• 起止时间: 2019-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/analysing-immune-response-therapy-cancer/1379513
• 关键词: Analysing; immune; response; optimising; effectiveness

Chimeric Antigen Receptor (CAR) T-cells have engineered receptors attached to patient immune cells. They target cancer with less risk of damage to healthy cells. Our laboratory manufactures CAR T-cells targeting a tumour marker- mesothelin, found on pancreatic and other cancers. I plan to test these CAR T-cells in vitro and in mice followed by enrolling cancer patients in a clinical trial of CAR T-cells. My aim is to monitor safety, efficacy and help improve patient survival and quality of life.

嵌合抗原受体（CAR）T细胞具有附着于患者免疫细胞的工程化受体。它们靶向癌症，对健康细胞的损害风险较小。我们的实验室生产CAR T细胞，靶向肿瘤标记物-间皮素，在胰腺癌和其他癌症中发现。我计划在体外和小鼠中测试这些CAR T细胞，然后在CAR T细胞的临床试验中招募癌症患者。我的目标是监测安全性、有效性，并帮助改善患者生存率和生活质量。